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A B S T R A C T
Purpose
This is a randomized, double-blind, placebo-controlled study aimed to evaluate the clinical
and biologic effects of letrozole plus lapatinib or placebo as neoadjuvant therapy in hormone
receptor (HR) –positive/human epidermal growth factor receptor 2 (HER2) –negative operable
breast cancer.
Methods
Ninety-two postmenopausal women with stage II to IIIA primary breast cancer were randomly
assigned to preoperative therapy consisting of 6 months of letrozole 2.5 mg orally daily plus
lapatinib 1,500 mg orally daily or placebo. Surgery was performed within 2 weeks from the last
study medication. Clinical response was assessed by ultrasonography. Pre- and post-treatment
samples were evaluated for selected biomarkers. Fresh-frozen tissue samples were collected for
genomic analyses.
Results
Numerically similar clinical response rates (partial  complete response) were observed (70% for
letrozole-lapatinib and 63% for letrozole-placebo). Toxicities were generally mild and manageable.
A significant decrease in Ki-67 and pAKT expression from baseline to surgery was observed in both
arms. Overall, 34 patients (37%) had a mutation in PIK3CA exon 9 or 20. In the letrozole-lapatinib
arm, the probability of achieving a clinical response was significantly higher in the presence of
PIK3CA mutation (objective response rate, 93% v 63% in PIK3CA wild type; P  .040).
Conclusion
The combination of letrozole-lapatinib in early breast cancer was feasible, with expected and
manageable toxicities. In unselected estrogen receptor–positive/HER2-negative patients, letrozole-
lapatinib and letrozole-placebo resulted in a similar overall clinical response rate and similar effect
on Ki-67 and pAKT. Our secondary end point findings of a significant correlation between PIK3CA
mutation and response to letrozole-lapatinib in HR-positive/HER2-negative early breast cancer
must now be independently confirmed.
J Clin Oncol 32:1050-1057. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Preoperative chemotherapy is the standard treat-
ment for locally advanced and inflammatory breast
cancer and is currently adopted for treatment of
larger primary tumors to improve the chance for
breast conservation. In patients with hormone re-
ceptor (HR) –positive/human epidermal growth
factor receptor 2 (HER2) –negative tumors, how-
ever, the rate of pathologic complete response
(pCR) after neoadjuvant chemotherapy is generally
less than10%,questioningtheeffectivenessofchem-
otherapy in this breast cancer subtype and the value
of pCR as a surrogate end point for outcomes.1-3
With the growing understanding of tumor biology
and molecular subtypes, endocrine manipulation
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has become the cornerstone of therapy for HR-positive tumors, and
neoadjuvant hormonal therapy is recently emerging as an attractive
option for patients with this breast cancer subtype.4-6 However, a
significant proportion of patients show primary or acquired resistance
to hormonal therapy. The cross-talk between estrogen receptor and
other growth factor receptor families, including the epidermal growth
factor receptor (EGFR) family, is suggested to play a crucial role in the
development of endocrine resistance.7 Several studies combining
EGFR-targeted agents with hormonal therapy have been conducted in
early and advanced disease, producing conflicting results.8-11
Lapatinib is a small-molecule, dual inhibitor of the tyrosine ki-
nase activity of EGFR and HER2 and is currently approved in patients
with HER2-positive advanced breast cancer who experience treat-
ment failure with trastuzumab-based therapy.12,13 We designed this
phase II, randomized study to evaluate the role of adding blockade of
both EGFR and HER2 to endocrine therapy in patients with HR-
positive/HER2-negative primary breast cancer. The aims of this study
were to evaluate the activity, safety, and biologic effects of letrozole-
lapatinib and letrozole-placebo.
METHODS
Study Design
This was a double-blind, placebo-controlled, randomized phase IIB study.
Postmenopausal women with HR-positive/HER2-negative, stage II to IIIA pri-
mary breast cancer were randomly assigned to receive letrozole-lapatinib (arm A)
or letrozole-placebo(armB).Theprimaryendpointwasbreastobjectiveresponse
rate (complete plus partial response), as assessed by ultrasonography.
Secondary aims included pCR rate in the breast and axillary lymph
nodes; percentage of breast-conserving surgery (BCS); safety profile of
study treatments; time to treatment failure (defined from start of primary
therapy to the occurrence of local or distant tumor progression, permanent
treatment discontinuation, or death from any cause); the percent inhibi-
tion of biomarkers of proliferative and apoptosis pathways; and the rela-
tionship between gene expression profile, copy number variations, somatic
mutations (including but not limited to PI3KCA), and protein biomarkers
and clinical/biologic response. The protocol was approved by ethical com-
mittees of participating institutions.
Patients
Patients were eligible if they met the following criteria: previously un-
treated, infiltrating primary breast cancer of more than 2.0 cm in largest
clinical diameter; estrogen and/or progesterone receptor positivity ( 10% of
positive cancer cells by immunohistochemistry [IHC]); HER2 negativity (ei-
ther IHC 0 to 1 or fluorescent in situ hybridization negativity by local
assessment); postmenopausal status; Eastern Cooperative Oncology Group
performance status of 0 to 1; left ventricular ejection fraction (LVEF) within
the normal range; normal organ and marrow function; ability to swallow and
retain oral medication; and written informed consent.
Study Procedures
At diagnosis, patients underwent a complete staging to exclude distant
metastases. Local disease extent was evaluated by mammography, breast ultra-
sonography, and clinically by caliper. Random assignment was performed
centrally at the Modena University Hospital Trial Office, through a dedicated
Web site with password-restricted access. Random assignment sequence was
generated using R software (http://www.r-project.org/). Patients were ran-
domly assigned 1:1 in a double-blind manner to letrozole 2.5 mg orally (PO)
daily plus lapatinib 1,500 mg PO daily (arm A) or letrozole 2.5 mg PO daily
plus lapatinib-matched placebo daily (arm B). Treatment was administered
over a 28-days cycle for six cycles. LVEF evaluation was repeated every third
cycle. Surgery was planned within 2 weeks after last study drug administration.
After surgery, hormonal therapy was given for up for 5 years, whereas adjuvant
chemotherapy was administered at the discretion of the treating physician.
Radiation therapy was planned according to local guidelines. Clinical exami-
nation, hematology, complete blood chemistry, carcinoembryonic antigen,
CA 15-3, chest radiogram, and liver ultrasound were planned every 6 months
for the first 3 years, and then yearly up to 5 years. Mammography was repeated
yearly. An independent data monitoring committee periodically evaluated
adverse events (AEs) and patient outcomes.
Assessment of Response and Toxicity
The clinical response was defined comparing the tumor size (largest
breast tumor diameter) before and at the end of cycle 6, as assessed by ultra-
sound examination. Response was evaluated according to criteria based on
modified RECIST guidelines. Complete response (CR) is defined as disappear-
ance of primary tumor. Partial response (PR) is defined as at least a 30%
decrease of the tumor’s longest diameter. Progressive disease (PD) is defined as
a more than 20% increase of the tumor’s longest diameter. Stable disease (SD)
is defined as neither sufficient shrinkage to qualify for PR nor sufficient in-
crease to qualify for PD. pCR is defined as complete absence of infiltrating
tumor cells in the breast and axillary lymph nodes.
Toxicities were graded according to the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events version 3.0 and reported as
cumulative incidence. All the analyses were conducted according to the
intention-to-treat (ITT) principle. The ITT population comprised all enrolled
patients who received at least one dose of study drug.
Sample Size Calculation and Statistics
The study used Simon’s two-stage design in each arm, based on an
expected rate of clinical objective response (cOR) of 50% with letrozole. The
combination of lapatinib-letrozole was considered worthwhile if the cOR rate
reached 70%. Setting  10% and  10%, the resulting sample sizes were
46 patients for arm A and 45 patients for arm B. A formal comparison of the
two arms was not planned. Random assignment was used to reduce bias as a
result of patient selection into treatment arms. All data were presented descrip-
tively as medians, means, or proportions. Biomarker changes from baseline to
surgery were evaluated using the Wilcoxon signed rank matched-pair test. The
association between biomarker expression and response was evaluated using
Pearson’s 2 test. Differences in mean biomarker inhibition were evaluated
using the t test. Statistical analyses were performed using STATA software V.10
(STATA, College Station, TX).
Biomarkers and Genomic Analyses
Formalin-fixed paraffin-embedded tumor blocks from diagnostic core
biopsies and from surgical specimen after preoperative study therapy were
centralized and reviewed for quality and tumor content. Fresh-frozen samples
from the diagnostic core biopsy were centralized for genomic studies.
IHC and Assessment of the Apoptotic Index
HER2 was centrally re-evaluated on diagnostic core biopsies. The follow-
ing biomarkers were evaluated on diagnostic core biopsy and on surgical
specimen following preoperative therapy: Ki-67, PTEN, pAKT, and pEGFR.
The antibodies used were as follows: HER2 (MoAb HER2, clone 4B5; Ventana,
Tucson, AZ), Ki-67 (clone Ki-67-MIB-1; DAKO, Carpinteria, CA), pAKT (Ser
473; Cell Signaling Technology, Beverly, MA), PTEN (clone 28H6; Novocas-
tra, Buffalo Grove, IL), and pEGFR (Tyr 1068; Cell Signaling Technology).
IHC staining was performed according to the avidin-biotin method, using
tissue sections of 3m in thickness. The following parameters were recorded:
presence or absence of immunoreactivity (diffuse or focal), cell types exhibit-
ing a positive reaction (tumor, endothelial, stromal, and inflammatory cells),
and percentage of immunostained tumor cells. HER2 fluorescent in situ hy-
bridization analysis (PathVysion HER-2 DNA Probe Kit; Vysis, Downers
Grove, IL) was performed in any case of HER2 IHC 2 and in cases of
discordance between the local and central laboratory.
Tissue sections were stained using the terminal deoxynucleotidyl trans-
ferase biotin-dUTP nick end labeling method, according to the standard
procedure included in the Apop Tag Plus In Situ Apoptosis Detection Kit
(Chemicon International, Temecula, CA). The percentage of apoptotic events
per cells population, by counting at least 3,000 malignant cells randomly
selected at400 magnification, was recorded.
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PI3KCA Mutation Analysis
Three 5-m, formalin-fixed paraffin-embedded sections of a primary
lesion containing at least 50% tumor cells were deparaffinized and incubated
in lysis buffer with proteinase K (50 mmol/L Tris, 1 mmol/L EDTA, 05%
Tween-20) at 56°C overnight. Genomic DNA was extracted with QIAmpl
DNA Mini Kit (Qiagen, Hilden, Germany). DNA concentration was deter-
mined using the NanoDrop 2000 spectrophotometer (Nano Drop Products,
Wilmington, DE). Genetic analysis of thePIK3CA gene was performed using a
commercially available PIK3CA status kit (certified European Conformity in
Vitro Diagnostic for diagnostic use; Diatech Pharmacogenetics, Jesi, Ancona,
Italy). The kit permits the identification of mutations in codons 542, 545, and
546 of exon 9 (E542K, E545K, E545A, E545G, Q546E, Q546K) and codons
1043, 1047, and 1049 of exon 20 (M1043I, H1047Y, H1047R, H1047L,
G1049R, G1049S) of thePIK3CA gene. A real-time polymerase chain reaction
(RotorGene 6000, Qiagen) was carried out using 30 ng of DNA as template.
Specific mutations were subsequently identified by pyrosequencing on Pyro-
Mark Q96 ID (Qiagen).
Molecular Studies
Genomic DNA and total RNA were extracted from pretreatment frozen
core biopsies of the primary tumor. RNA samples that met the quality require-
ments were processed according to the Affymetrix GeneChip 3 IVT Express
Kit user’s manual (Affymetrix, Santa Clara, CA).
DNA samples were processed by using the Affymetrix Genome-wide
Human SNP array. See Data Supplement for detailed description of sample
processing and analysis.14
RESULTS
Ninety-two patients were randomly assigned, 43 patients to letrozole-
lapatinib (arm A) and 49 patients to letrozole-placebo (arm B; Fig 1).
Baseline patient characteristics were balanced between the two arms
(Table 1).
Compliance With Treatment and Toxicity
Overall, nine patients prematurely discontinued treatment, five
in arm A (PD, n1; AEs, n2; informed consent withdrawn, n2)
and four in arm B (PD, n  2; suspected metastatic disease, n  1;
informed consent withdrawn, n 1). Ten patients required lapatinib
or placebo dose reduction, nine in the letrozole-lapatinib arm and one
in the letrozole-placebo arm.
The safety analyses included all randomly assigned patients. As
expected, skin disorders, diarrhea, and liver function test abnormali-
ties occurred more frequently in lapatinib-treated patients. One epi-
sode of grade 4 skin toxicity was reported in one patient randomly
assigned to the letrozole-lapatinib arm. In arm B (letrozole-placebo),
AEs of grade 2 were infrequent (Table 2).
Cardiac function was preserved over time. The mean LVEF at
baseline and at weeks 12 and 24 from starting therapy were 61%,
60.1%, and 58.6%, respectively, in the letrozole-lapatinib arm and
61%, 62.6%, and 60.5%, respectively, in the letrozole-placebo group.
Arm A: letrozole-lapatinib
   Allocated to intervention
   Received allocated intervention
(n = 43)
(n = 43)
Arm B: letrozole-placebo
   Allocated to intervention
   Received allocated intervention
(n = 49)
(n = 49)
)94 = n(ytefas rof dezylanA)34 = n(ytefas rof dezylanA
Analyzed for efficacy (n = 43) Analyzed for efficacy (n = 49)
Random assignment
(N = 92)
Fig 1. CONSORT diagram.
Table 1. Patient Clinical and Tumor Characteristics
Characteristic
Arm A, Letrozole-
Lapatinib (n  43)
Arm B, Letrozole-
Placebo (n  49)
No. of
Patients %
No. of
Patients %
Age, years
Median 70 70
Range 49-88 47-88
ECOG PS
0 41 95.35 45 91.8
1 2 4.65 3 6.12
NA — — 1 2
Clinical stage
IIA 21 48.8 26 53
IIB 17 39.5 21 42.9
IIIA 5 11.6 2 4.1
Histology
Ductal 29 67.4 38 77.6
Lobular 8 18.6 7 14.3
Mucinous 2 4.7 1 2
Other/not specified 4 9.3 3 6.12
Histologic grade
1 1 2.3 — —
2 16 37.2 19 38.8
3 13 30.2 19 38.8
NA 13 30.2 11 22.4
HER2 status
IHC 0 23 53.5 24 49.0
IHC 1 8 18.6 13 26.5
IHC 2/FISH not amplified 5 11.6 4 8.2
FISH not amplified 7 16.3 8 16.3
ER expression, %
Mean 89 90
Range 40-100 30-100
PgR expression, %
Mean 56 52
Range 0-100 0-100
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance
status; ER, estrogen receptor; FISH, fluorescent in situ hybridization; HER2,
human epidermal growth factor receptor 2; IHC, immunohistochemistry; PgR,
progesterone receptor; NA, not available.
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One patient in the letrozole-lapatinib arm who experienced clinical
symptoms of congestive heart failure not considered related to study
drug fully recovered from the event.
Surgery and Responses
Eighty-one of 92 patients were evaluable by ultrasonography;
eight patients were assessed by mammography and/or palpation.
Three patients discontinued therapy and withdrew consent and were
counted as nonresponders according to the ITT analysis.
Central radiology review was performed. The cOR rate
(CRPR) was similar in the two arms (70% and 63% in the letrozole-
lapatinib and the letrozole-placebo arms, respectively).
The distribution of responses in the two arms was as follows: arm
A: CR, 12%; PR, 58%; SD, 23%; and PD, 2%; and arm B: CR, 2%; PR,
61%; SD, 29%; and PD, 6%. When limiting the analysis to patients
evaluable by ultrasound, the cOR rate was 69.2% in the letrozole-
lapatinib arm and 57.8% in the letrozole-placebo arm.
Forty-two of 43 patients randomly assigned to arm A underwent
surgery; 27 patients (62.8%) received BCS, and 15 patients (34.9%)
received mastectomy. The conversion rate from mastectomy to BCS
was 46% (six of 13 patients). Forty-seven of 49 patients randomly
assigned to arm B underwent surgery; 35 patients (71.4%) received
BCS, and 12 patients (24.5%) received mastectomy. The conversion
rate from mastectomy was 58.9% (10 of 17 patients). No pCR was
observed in the two arms.
Biomarkers and Genomic Analyses
All primary tumor samples were confirmed as HER2 negative by
central review. Biomarker analysis results are listed in Table 3. A
significant reduction in Ki-67 and pAKT expression was observed
between pre- and post-treatment samples (Fig 2). In particular, mean
Ki-67 expression decreased from 18.7% to 12.8% in the letrozole-
lapatinib arm (P .002) and from 19.2% to 12.8% in the letrozole-
placebo arm (P .001). No differences in the mean Ki-67 suppression
were observed between the two arms, consistent with the similar cOR
rates. The mean Ki-67 suppression tended to be higher in responders
versus nonresponders and in patients with PIK3CA mutation versus
wild type (WT) in the letrozole-lapatinib arm. The Data Supplement
summarizes the mean Ki-67 suppression overall, according to re-
sponse and toPIK3CA status in the two arms. A significant decrease in
apoptosis was also observed in the letrozole-lapatinib arm.
Table 3. Biomarker Expression Analyses
Biomarker
Baseline Surgery
PNo. of Patients
Expression (%)
No. of Patients
Expression (%)
Mean Range Mean Range
Arm A, letrozole-lapatinib
Ki-67 41 18.7 2-48 39 12.8 1-50 .002†
pAKT 41 12.2 0-90 36 2.36 0-60 .0148†
PTEN 38 70.3 0-100 33 75.1 0-100 .4843
pEGFR 41 0.49 0-20 39 0.77 0-30 .9845
TUNEL 36 0.47 0.05-1.2 27 0.33 0.05-1.4 .0158†
Arm B, letrozole-placebo
Ki-67 49 19.2 2-60 46 12.8 1-45  .001†
pAKT 47 16.8 0-90 46 7.98 0-80 .0323†
PTEN 40 71.4 0-100 40 71.6 0-100 .5373
pEGFR 48 0.31 0-15 46 0.43 0-20 .9873
TUNEL 40 0.44 0.05-1.7 30 0.33 0.05-2 .1142
Abbreviations: pAKT, phosphorylated AKT; pEGFR, phosphorylated epidermal growth factor receptor.
Wilcoxon signed rank test (from baseline).
†Significant value.
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Fig 2. Individual Ki-67 changes from baseline to surgery in (A) arm A (letrozole-
lapatinib) and (B) arm B (letrozole-placebo).
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A mutation in PIK3CA exon 9 or 20 was observed in 37% of the
patients. Specifically, 14 patients (15.2%) had mutation in exon 9, and
22 patients (23.9%) had mutation in exon 20. One patient was con-
firmed as having mutations in both exons (Data Supplement). The
cOR rate tended to be higher in patients with PI3KCA-mutated tu-
mors, despite not reaching statistical significance (cOR rate, 76% in
PI3KCA-mutated v 59% in PI3KCA WT tumors; P  .09). In the
letrozole-lapatinib arm, this difference was more marked (93% in
mutated v 63% in WT tumors; P  .037), whereas in the letrozole-
placebo arm, the cOR rate was similar between mutated and WT
tumors (63% v 66%, respectively; P  .79). Individual responses
according to PI3KCA status are presented in Figure 3. Results of gene
expression analyses and copy number data are available in the
Data Supplement.
DISCUSSION
The EGFR and HER2 cross-talk with estrogen receptor signaling rep-
resents a potential mechanism of escape to endocrine therapy. On
these premises, we have designed this study to evaluate the clinical and
biologic effects of cotargeting both these pathways in HR-positive/
HER2-negative patients.
The overall response rate was similar in the two arms (70% for
letrozole-lapatinib and 63% for letrozole-placebo). The overall re-
sponse rate in the letrozole-lapatinib arm reached the prespecified
70% target; however, the letrozole-placebo arm outperformed the
expected 50% objective response rate. The inhibition of the HER2-
EGFR pathway does not seem to provide additional benefit in endo-
crine therapy–naive HR-positive/HER2-negative disease.
These results are consistent with those observed in the metastatic
setting. Indeed, in the HER2-negative population of EGF30008 study,
no difference was observed in median progression-free survival. How-
ever, according to a preplanned exploratory analysis, a trend in
progression-free survival improvement with the combination of
lapatinib-letrozole was observed in the HER2-negative subgroup,
which experienced progression within 6 months from prior tamox-
ifen, suggesting activation of the EGFR pathway as an escape mecha-
nism to endocrine blockade.13
The conversion rate from mastectomy to BCS tended to be
higher in the placebo arm; however, the decision to offer BCS depends
on several parameters, such as breast size, tumor location, presence of
ductal carcinoma in situ, contraindication to radiation therapy, and
patient decision. No patient achieved a pCR, as expected from neoad-
juvant hormonal therapy trials.4-6,15,16
The biomarker analyses showed a significant decrease of Ki-67
and of pAKT expression in both arms. Inhibition of Ki-67 was similar
in the two treatment arms, which was consistent with the similar
response rates observed. Indeed, previous studies have suggested a
correlation between a decreased Ki-67 and treatment efficacy.17,18
Akt is a serine/threonine kinase that plays an important role in
survival when cells are exposed to different apoptotic stimuli, and
constitutive activation of the PI3K/Akt pathway has been impli-
cated as one of the mechanisms of resistance to hormonal
therapy.19-21 We have previously reported a significant decrease of
pAKT after neoadjuvant chemotherapy plus trastuzumab and/or
lapatinib in HER2-positive breast cancer.22,23 The decrease of
pAKT in both arms is consistent with the high clinical response rate
observed in these patients.
The more interesting finding is the relationship betweenPI3KCA
mutation and response. Although not statistically significant, overall,
the presence of PI3KCA deregulation was associated with a numeri-
cally higher clinical response rate. This difference is mainly driven by
the letrozole-lapatinib arm, where the presence of PI3KCA mutations
predicted for higher chance of responding to treatment. These data
suggest a potential benefit of adding lapatinib to letrozole when a
deregulation of the PI3K/Akt pathway is documented. Indeed, at least
in the HER2-positive setting, preclinical and clinical evidence suggests
that deregulation of this pathway may be a marker of trastuzumab
resistance while sensitivity to lapatinib is retained.24-26 In HER2-
negative disease, the hypothesis is that tumors harboring PI3KCA
mutations rely more on GFR/PI3K signaling than on estrogen for
growth; thus, blocking growth factor receptor signaling with lapatinib
might restore hormonal sensitivity. Indeed, the PI3K pathway influ-
ences estrogen and progesterone receptor levels and activity, and a
large body of experimental and clinical evidence suggests that hyper-
activation of the PI3K pathway promotes antiestrogen resistance.27
The combination of letrozole-lapatinib was feasible. Toxicities,
generally mild and manageable, are expected with the use of lapatinib
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Fig 3. Individual response and PI3KCA mutations. Waterfall plots of individual
tumor response (percent change from baseline) in (A) arm A (letrozole-lapatinib)
and (B) arm B (letrozole-placebo). Blue bars represent patients with PI3KCA wild
type; gold bars represent patients with PI3KCA mutations. (*) Mutations in exon
9. (†) Mutations in exon 20. (‡) Mutations in both exons.
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and other tyrosine kinase inhibitors (skin rash, diarrhea, and liver
function test alterations). Nevertheless, these toxicities are clinically
relevant even if low grade, because these AEs can persist for the entire
treatment duration. Definitively, given the similar clinical activity and
the greater toxicity, the combination of letrozole-lapatinib cannot be
considered a potential interesting option for HR-positive/HER2-
negative patients. However, our data suggest that patients whose
tumors harborPI3KCAmutations might benefit more from letrozole-
lapatinib, thus justifying the higher toxicities. Nevertheless, our find-
ings are based on a limited sample size, and an independent validation
on a larger cohort is necessary.
Other studies have explored the role of combining targeted
agents to endocrine therapy in the neoadjuvant setting. In a random-
ized trial conducted in women with HR- and EGFR-positive tumors,
gefitinib monotherapy induced tumor shrinkage in 54% of patients,
whereas the combination of gefitinib plus anastrozole versus gefitinib
alone resulted in a greater inhibition of tumor proliferation.8
In another preoperative trial, everolimus added to letrozole sig-
nificantly increased the clinical response rate and was associated with a
higher inhibition of Ki-67 after 15 days of therapy compared with
letrozole-placebo.28 These and other studies underline the importance
of conducting relatively small neoadjuvant studies with mandatory
tissue sample collection.
Other studies have addressed the role of cross-talk between HR
and growth factor receptor pathways; these studies, however, have
been conducted in different patient populations and/or by using dif-
ferent tyrosine kinase inhibitors. Our study is the first prospective
randomized phase II trial conducted in the neoadjuvant setting to
explore the role of lapatinib in HR-positive/HER2-negative operable
breast cancer and to relate biomarker expression and/or modulation
with treatment efficacy.
In conclusion, our study demonstrated that, in HR-positive/
HER2-negative patients, letrozole-lapatinib and letrozole-placebo re-
sulted in a similar clinical response rate and similar effects on Ki-67
and pAKT. Our secondary end point findings of a significant correla-
tion betweenPIK3CAmutation and response to letrozole-lapatinib in
HR-positive/HER2-negative early breast cancer must now be inde-
pendently confirmed.
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GLOSSARY TERMS
EGFR (epidermal growth factor receptor): (also
known as HER1) belongs to a family of receptors (HER2, HER3,
HER4 are other members of the family) and binds to the EGF,
TGF-, and other related proteins, leading to the generation of
proliferative and survival signals within the cell. It also belongs to
the larger family of tyrosine kinase receptors and is generally
overexpressed in several solid tumors of epithelial origin.
gene expression profile: the expression of a set of genes in
a biologic sample (eg, blood, tissue) using microarray, reverse-
transcriptase polymerase chain reaction, or other technology ca-
pable of measuring gene expression.
Ki-67: a marker of proliferation. Ki-67 is a protein that is ex-
pressed in the nucleus of proliferating cells. It is absent only in
resting cells. Cells in the G1, S, G2, and M phase of the cell cycle
express this marker.
phospho-AKT: the phosphorylated form of AKT, which is the acti-
vated form of the molecule.
phospho-EGFR: the phosphorylated (ie, activated) form of the epi-
dermal growth factor receptor, which is the activated form of the mole-
cule. See EGFR (epidermal growth factor receptor).
PIK3CA: the catalytic subunit of phosphatidylinositol 3-kinase in-
volved in the generation of PIP3 which, in turn, leads to the activation
of AKT and other oncogenic kinases. Mutations in the PIK3CA gene
have been found in a number of cancers, including ovarian, breast, co-
lon, and lung carcinomas. See PI3K and AKT/PKB.
PTEN: a tumor suppressor gene with a gamut of regulatory activities.
The gene product is a multifunctional molecule. The predominant ac-
tivity identified for PTEN is its lipid phosphatase activity that converts
inositol trisphosphates into inositol bisphosphates, thus inhibiting sur-
vival and proliferative pathways that are activated by inositol trisphos-
phates. PTEN acts to maintain arrest in the G1 phase of the cell cycle
and enable apoptosis through an AKT-dependent mechanism.
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